Bleeding due to an acquired inhibitor of platelet associated factor V.
Factor V inhibitors are uncommon, bleeding manifestations variable and recommendations for management are unclear. We present a patient with non-Hodgkins lymphoma who developed gastrointestinal bleeding and was found to have a Factor V inhibitor. The inhibitor was active against both plasma Factor V and platelet associated Factor V, and was associated with a five-fold increase in platelet associated IgG. Fresh frozen plasma was ineffective in preventing bleeding. Resolution of bleeding was associated with a fall in the levels of the inhibitor and of platelet associated IgG. The patient had no further bleeding episodes nor evidence of progression of his lymphoma, but six months later died as a result of metastatic adenocarcinoma.
Grigg
A P
AP
Austin Hospital, Melbourne, Australia.
Dauer
R
R
Thurlow
P J
PJ
D000230:Adenocarcinoma / Q000556:secondary; D000368:Aged; D001778:Blood Coagulation Disorders / Q000097:blood / Q000150:complications*; D001779:Blood Coagulation Factors / Q000037:antagonists & inhibitors*; D001792:Blood Platelets / Q000378:metabolism*; D005166:Factor V Deficiency / Q000097:blood / Q000150:complications*; D006471:Gastrointestinal Hemorrhage / Q000097:blood / Q000209:etiology*; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications; D008297:Male; D010314:Partial Thromboplastin Time; D010977:Platelet Factor 3 / Q000037:antagonists & inhibitors; D011517:Prothrombin Time
D001779:Blood Coagulation Factors; D007074:Immunoglobulin G; C037685:platelet factor V; D010977:Platelet Factor 3